A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis
Phase 3
- Conditions
- lcerative Colitis
- Registration Number
- JPRN-jRCT2080220713
- Lead Sponsor
- JANSSEN PHARMACEUTICAL K.K
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Have received all study agent administrations and completed the Week 6 Mayo score evaluation in one of the induction studies of CNTO 148 (golimumab) for (UC) Ulcerative Colitis
Exclusion Criteria
Had changes to concomitant UC medications since Week 0 of an induction study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method